Immuno-protective vesicle-crosslinked hydrogel for allogenic transplantation

Nat Commun. 2024 Jun 18;15(1):5176. doi: 10.1038/s41467-024-49135-x.

Abstract

The longevity of grafts remains a major challenge in allogeneic transplantation due to immune rejection. Systemic immunosuppression can impair graft function and can also cause severe adverse effects. Here, we report a local immuno-protective strategy to enhance post-transplant persistence of allografts using a mesenchymal stem cell membrane-derived vesicle (MMV)-crosslinked hydrogel (MMV-Gel). MMVs are engineered to upregulate expression of Fas ligand (FasL) and programmed death ligand 1 (PD-L1). The MMVs are retained within the hydrogel by crosslinking. The immuno-protective microenvironment of the hydrogel protects allografts by presenting FasL and PD-L1. The binding of these ligands to T effector cells, the dominant contributors to graft destruction and rejection, results in apoptosis of T effector cells and generation of regulatory T cells. We demonstrate that implantation with MMV-Gel prolongs the survival and function of grafts in mouse models of allogeneic pancreatic islet cells and skin transplantation.

MeSH terms

  • Allografts
  • Animals
  • B7-H1 Antigen / immunology
  • Cell Membrane* / immunology
  • Cell Proliferation
  • Cross-Linking Reagents* / chemistry
  • Fas Ligand Protein / immunology
  • Female
  • Graft Survival
  • Hydrogels* / chemistry
  • Islets of Langerhans / immunology
  • Islets of Langerhans / surgery
  • Islets of Langerhans Transplantation*
  • Lymphocyte Activation
  • Mice
  • Skin / immunology
  • Skin Transplantation*
  • Stem Cells / immunology
  • T-Lymphocytes / immunology
  • Transplantation, Homologous

Substances

  • Cross-Linking Reagents
  • Hydrogels
  • Fas Ligand Protein
  • B7-H1 Antigen